News Square
Global Crypto News · Real-time Aggregation
📚 Deep Analysis
More →GRVT Burns 1.1 Million Tokens as Countdown to Grvt 2.0 Begins
<strong>[PRESS RELEASE – Singapore, Singapore, October 20th, 2026]</strong> <strong>The discretionary buyback represents close to 1% of circulating supply and precedes four planned product milestones culminating in Grvt 2.0.</strong> <a href="https://grvt.io/" rel="nofollow noopener" target="_blank">>Grvt</a>, a self-custodial trading platform built on its own zero-knowledge (ZK) chain, announced that the Foundation’s token issuer has completed its first GRVT token buyback, purchasing and burning 1.1 million GRVT tokens on the open market. The transaction permanently removed close to 1% of GRVT’s circulating supply at the time of purchase. It marks the first of five milestones ahead of the planned launch of Grvt 2.0 at the end of November 2026. <strong>A Discretionary Buyback with On-Chain Verification</strong> The Foundation’s token issuer intends to conduct further buybacks on a monthly basis. Each transaction remains entirely at the issuer’s discretion, with no predetermined purchase amount or guaranteed schedule. Buybacks are executed through an independent execution partner, with purchased tokens transferred to a designated burn address and permanently removed from circulation. The transactions can be independently verified through the <a href="https://grvt.io/exchange/buybacks" rel="nofollow noopener" target="_blank">>public buyback dashboard</a>, which records the number of tokens purchased and burned, the percentage of circulating supply represented, cumulative burns and on-chain transaction hashes. “The GRVT token is an important part of the ecosystem we are building,” said <strong>Hong, co-founder and CEO of Grvt</strong>. “We welcome the issuer’s buybacks as a demonstration of its long-term commitment to the ecosystem and community. Grvt is expanding its products and markets, and the issuer’s buybacks sit alongside that as a supportive mechanism aimed at reducing circulating token supply.” <strong>Grvt Outlines Four Product Milestones</strong> The announcement follows GRVT’s token generation event in July 2026 and precedes a series of planned launches. <strong>Grvt Earn, scheduled for the End of October,</strong> will introduce yield opportunities backed by tokenized assets, with target yields of up to 11%. Potential returns are expected to derive from underlying asset cash flows, including interest, premiums and invoice-related income. Asset-supplying partners will be announced at launch. Target yields are not guaranteed. <strong>Stable Funding Perps, scheduled for November,</strong> will introduce perpetual futures linked to commodities, stocks, foreign exchange and indices. The contracts are planned to carry zero trading fees and use once-daily funding. Grvt aims to list more than 1,000 markets by the end of December 2026. <strong>Yield as Margin, also scheduled for November,</strong> will allow eligible Grvt Earn balances to support trading positions while continuing to accrue yield, subject to applicable product terms
OpenAI Buys Orchestra Bio to Put AI Agents in Charge of Drug Development Grunt Work
OpenAI has bought Orchestra Bio, a San Francisco startup whose AI agents help drug companies keep sprawling development programs on schedule, the ChatGPT maker <a href="https://openai.com/index/openai-to-acquire-orchestra-bio/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>announced Tuesday</a>. “Our goal is to help scientists make discoveries and manage the work needed to turn them into treatments that reach patients sooner,” OpenAI said in the announcement. Orchestra’s team and platform will be folded into <a href="https://openai.com/rosalind/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>Rosalind</a>, OpenAI’s family of AI models and tools for biologists and chemists. The financial terms were not disclosed. Getting a new medicine from first idea to U.S. approval takes time—up to 15 years according to OpenAI. Every month shaved off that timeline is a month earlier that a new treatment can reach the people waiting for it, and a month earlier that the company can generate cash. The process is also absurdly expensive: bringing one approved drug to market can cost more than <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12668846/" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>$2.6 billion</a>, and <a href="https://arxiv.org/pdf/2106.05386" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">fewer than 10%</a> of candidates that enter human testing ever make it to pharmacy shelves. Beyond the science itself, OpenAI says drug teams have to coordinate work across internal departments and outside partners, often relying on systems that don’t talk to each other. Those partners usually include contract research organizations, the outside labs hired to run studies, and contract manufacturers that produce the experimental drug. Orchestra’s AI agents—software that can watch over tasks and flag problems on its own—work out which activities and deadlines take the hit, gather the relevant information and compare ways to respond, while scientists and program leaders make the final call. Founded in the fall of 2022, Orchestra raised its <a href="https://jobs.8vc.com/companies/orchestra/jobs/28818089-senior-software-engineer" target="_blank" rel="nofollow external noopener" class="sc-adb616fe-0 dJryYS">>seed round</a> from Andreessen Horowitz, Definition Capital, Insight Partners, and 8VC, and about $20 million in total, according to <a href="https://www.caplight.com/company/orchestra-bio" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">Caplight data</a>. The company should not be confused with Orchestra BioMed, an unrelated Nasdaq-listed medical device maker that trades under the ticker OBIO. In April, OpenAI launched <a href="https://decrypt.co/364783/openai-gpt-rosalind-drug-discovery-life-sciences-model" target="_blank" class="sc-adb616fe-0 dJryYS" rel="nofollow">GPT-Rosalind</a>, a model built specifically for biology and dru
Ben Horowitz: AI will enhance creativity and the value of interpersonal relationships.
Benzinga reports that Andreessen Horowitz co-founder Ben Horowitz said that as AI takes over more routine work, creativity and the value of interpersonal relationships will become more important. He pointed out that AI already performs very well in handling repetitive tasks.
The total market capitalization of the crypto market stands at 2.8 trillion US dollars.
According to Bijie data, the total market capitalization of the crypto market is $2.8 trillion, with a trading volume of $82.716 billion over the past 24 hours.
Musk: Companies such as ASML are accelerating the supply of chip manufacturing equipment for Terafab.
According to CoinWorld news, Musk said during SpaceX's third-quarter earnings call that ASML and other major semiconductor manufacturing equipment suppliers have accelerated equipment deliveries to Tesla and SpaceX's Terafab chip project. He noted: "These timelines are very tight, and we are very grateful to ASML and all the other suppliers for accelerating equipment deliveries to help us achieve this goal." Terafab is a large-scale chip manufacturing project planned by Musk for Tesla and SpaceX, aimed at meeting the two companies' enormous demand for AI processors and other chips, and making up for the shortfall in advanced chip supply from existing suppliers including TSMC. Musk said SpaceX aims to achieve mass production of chips at the Terafab factory in the third or fourth quarter of 2028.
Musk: Companies such as ASML are accelerating the supply of chip equipment for Terafab.
CoinWorld news: Musk said on SpaceX's third-quarter earnings call that ASML and other major semiconductor manufacturing equipment suppliers are accelerating equipment deliveries to Tesla and SpaceX's Terafab chip project. He noted that these timelines are very tight and thanked ASML and all other suppliers for their support. The Terafab project aims to meet the enormous demand from Tesla and SpaceX for AI processors and other chips, filling the gap in advanced chip supply from existing suppliers. Musk said SpaceX aims to achieve mass production of chips at the Terafab factory in the third or fourth quarter of 2028.
There is an 85% chance that OpenAI's valuation will exceed $1.25 trillion by the end of 2026.
According to Bijie news, the current market estimates that OpenAI has an 85% chance of exceeding a valuation of $1.25 trillion by the end of 2026.
The probability of the Federal Reserve keeping interest rates unchanged in October is 83.9%.
According to CoinWorld news, the CME "FedWatch" shows that the probability of the Federal Reserve keeping interest rates unchanged by October is 83.9%, and the probability of a cumulative 25 basis point rate hike is 16.1%. By December, the probability of keeping interest rates unchanged is 9.8%, the probability of a cumulative 25 basis point rate hike is 76.1%, and the probability of a cumulative 50 basis point rate hike is 14.2%.
SEC: Comment period for crypto proposal ends today, but feedback will still be accepted.
CoinWorld news, according to Eleanor Terrett, the SEC's comment period on its crypto proposal ends today, but a spokesperson said the commission will continue to accept public comments after the deadline. "While we encourage commenters to submit feedback before the deadline, the commission will continue to accept public comments on the rule proposal," the spokesperson said. The proposal would create a new fundraising exemption for crypto issuers raising funds in the United States.
Grayscale: AI compute demand remains strong; pullbacks are buying opportunities.
CoinWorld news, according to Cointelegraph, Grayscale stated that although computing infrastructure stocks have declined by about 27% since September, AI computing demand remains strong, and described the pullback as a buying opportunity.